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A MULTICENTER RANDOMIZED
STUDY OF TWO REGIMENS IN
PALlATIVE RADIOTHERAPY OF
BONE METASTASES.
A. Badzio, B. Jereczek-Fossa,
E. Senkus-Konefka, K. Adamska, I. Fajndt,
I. Tesmer-Laskowska, E. Janus-Kowalska,
J. Jassem
Medical University ot Gdansk, Great Poland
Cancer Center in Poznan, Cancer Center in
Lodz, Cancer Center in Bydgoszcz, Cancer
Center in Wroclaw.
In this study we compared two methods ot
radiotherapy in patients with painful bone
metastases: 20 Gy in five fraction in tive
consecutive days vs 8 Gy in one traction. Atotal
ot 115 patients (34 males, 81 temales), median
age 56 years (23-80), were randomly allocated
to one ot the treatment arms. In 56 pts. Primary
tumor was located in the breast, in 14 pts in the
lung, in ten pts in the kidney, in seven pts in the
prostate, and in 28 pts in other sites. A total ot
146 metastatic bone lesions were irradiated,
seventy tive (51 %) were treated with 20 Gy and
seventy one (49%) - with 8 Gy. The most
trequent location ot metastatic lesions was spine
(36%), tollowed by pelvis (25%), long bones
(18%), ribs (12%) and other sites (12%).
Treatment techniques included single tield
(73%) or two parallei opposed fields (27%).
Complete pain reliet was achieved in 36% ot the
lesions irradiated with 20 Gy and in 41 % ot
those irradiated with 8 Gy. Partial improvement
was observed in 46% and 43% ot lesions,
respectively. The median time to reappearance
ot pain in both groups was 5.4 a 4.8 months and
5.0 a 5.4 months respectively. We conclude that
a single exposure to 8 Gy is ot the same efficacy
as 20 Gy in five fractions in pain control ot bone
metastases and should be recommended as
routine management.
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HOW OFTEN MEDICAL LlTERATURE
MAY BE A SOURCE OF INCORRECT
CLlNICAL DECISION?
K. Bujko, M.P. Nowacki, W. Michalski
The M. Sklodowska-Curie Memorial Cancer
Centre and Institiute ot Oncology
Rep. Pract. Oncol. Radiother. 6 (1) 2001
Change in clinical practice results mainly from
positive randomized triais (superiority of tested
method confirmed by significant result of
statistical test). However, the rate of false
positive triaIs might be high among all positive
triaJs - even 30%-50%. This percentage
depends mainlyon the rate of triais with a real
difterence in efficacy between tested methods;
in lesser extend it depends on a level ot type II
error (a number ot patients in atrial). The
probabie high rate ot talse positive triais among
all positive triais indicates that a risk ot
undertaking of incorrect c1inical decision based
on literature may be also high. In addition, this
risk is increased due to publication bias.
Therefore, contirmatory triais are otten
necessary. The other issue, which might be a
source ot incorrect clinical decision, is lack of
data enabling an assessment of generalizability
ot trial results: 1. a number ot eligible but not
enrolled patients and the reasons for treatment
outside trial; 2. a comparison of a characteristic
ot patients on trial with a characteristic ot
eligible, but not enrolled patients; 3. a
comparison ot results ot treatment ot patients on
trial with results ot treatment ot eligible, but not
enrolled patients 4. data ot reterral pattern and
intormation on the source population, trom
which patients were selected.
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E. Bednaruk-Mlynski, R. Dziadziuszko,
J. Kubrak, A. Lewandowska, K. Malachowski,
M. Wierzchowski, J. Rzepecki,
E. Chyczewska, M. Matecka-Nowak.
Medical University ot Gdansk, Pomeranian
Medical University Szczecin, Regional Oncology
Center Bydgoszcz, Silesian Oncology Center
Wroc(aw, The Maria-Sklodowska-Curie
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Oncology, Maritime Hospital Gdynia, Medical
University of Bialystok, Greatpoland Cancer
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A prospective, randomized study was
conducted in eight Polish institutions to compare
the value ot two tractionation schemes ot
palliative radiotherapy tor inoperable non-smali
43
celi lung cancer. Assessed was the impact of
either treatment on the degree and duration of
relief of tumor-related symptoms and on
patient's performance status. Secondary
endpoints included treatment side-effects,
objective response and overall survival. One
hundred patients were randomly assigned to the
dose of 20 Gy/5x15 days (Arm A) or 16 Gy/2x18
days (Arm B). There were 90 men and 10
women aged between 47 and 79 (mean 66).
Eighty four patients had locally advanced tumor
and 16 patients had metastatic disease.
Squamous celi carcinoma was diagnosed in 65
patients, adenocarcinoma - in 9 patients, large
celi carcinoma - in 1 patient and unspecified
non-smali celi carcinoma - in 25 patients. Fifty
five patients were assigned to Arm A and 45 - to
Arm B. Ninety eight patients received assigned
treatment whereas twa patients died before the
end of treatment. The final results of the study
will be presented at the conference.
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MULTICENTER, RANDOMIZED
STUDY ASSESSING THE IMPACT OF
AMIFOSTINE ON NORMAL TISSUE
RADlATlON TOLERANCE DURING
HEAD AND NECK CANCER
RADIOTHERAPY
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E. Bednaruk-Mlynski, A. Badzio, J. Madrzak,
K. Matuszewska, A. Kawecki, E. Pietrusinska,
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Oncology
A prospective, randomized multicenter study
was conducted to assess the value of amifostine
(Ethyol®) as a radioprotectant in head and neck
cancer radiotherapy. The aim of the study was
to evaluate the impact of the addition of daily
amifostine (150 mg/m2) on the degree of early
(mucositis, dysphagia, xerostomia) and late
(mucosal, cutaneous, salivary gland, mandible
and spinaj cord) radiation reactions. Assessed
were aiso patients' quality of life, local control
and overall survival. Sixty two patients fram five
Polish institutions were randomly assigned to
radiotherapy alone (Arm A - 28 patients) or
radiotherapy + amifostine (Arm B - 34 patients).
There were 43 men and 19 women. Primary
44
tumor was located in the aral cavity (27
patients), oropharynx (25 patients), nasopharynx
(2 patients) and larynxlhypopharynx (8 patients).
In 43 patients radiotherapy was used as the sole
modality of tretatment and 19 patients were
irradiated postoperatively. The side effects of
amifostine were manageable. In 6 patients
amifostine intusion had to be temporarily
stopped due to hypotension and in 5 patients its
administration was permanently terminated due
to hypotension, nausea and vomiting,
septicemia or tever and visual disturbances. The
early results ot the study, tocusing on early
radiation reactions, will be presented at the
conterence.
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THE OWN EXPERIENCE IN
MONITORING THE LATE RADlATlON
REACTION OF CRITICUAL TISSUES
IN HEAD AND NECK REGION
M.Goleń\ K.Składowski\ A.Wygoda2
W.Przeorekl, B.Pilecki1 M.Sygułal,
Z. Kołosza 3
I Klinika Radioterapii1, Zakład Radioterapii2 ,
Zakład Epidemiologii3
Purpose: The estimation of scoring system
SOMA-LENT in classitication the late radiation
toxicity in patients with squamous celi cancer
irradiated in H&N region.
Material and methods:_The material includes
97 patients with orał cavity, pharyngeal and
supraglottic cancer T2•4No-1 irradited by
conventionał method (18 patients), continous
accelerated irradiation CAIR (42 patients) and
concomitant boost CB (37 patients). Total dose
was in range 66-74 Gy. The late radiation
taxicity was evaluated by SOMA-LENT system
for pharyngeal and aral cavity mucosal
membrane, skin, larynx, salivary glands, spinaj
cord. The estimation was done every
6 months after completing ot radiotherapy. In
statistical analysis the values were normalisated
to maximai intensity ot all symptoms in the
scale.
Results: The intensity ot late radiation toxicity
for mucosal membrane was increasing between
1i h-18 th month after radiotherapy and next
decreased from 24 after irradiation. For skin the
intensity of late radiation reaction increased to
24 months after treatment. For larynx we noticed
two peaks ot late radiation toxicity: between
18th_24th month and about 54 month after
irradiation. The intensity ot late radiation effect
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